Yves Henrotin, Prof.
Clinical and Scientific Advisor
Professor of Pathology, Physical Therapy and Rehabilitation and Director of the Bone and Cartilage Research Unit at the University of Liège, Belgium; President of Osteoarthritis Foundation.
Prof. Yves Henrotin is an internationally renowned Key Opinion Leader with outstanding scientific and clinical expertise in osteoarthritis (OA), low back pain and other musculoskeletal disorders, and vast experience in setting up and running OA clinical trials (from Phase 1 to Phase 4).
Yves Henrotin is professor of pathology, physical therapy and rehabilitation and director of the Bone and Cartilage Research Unit at the University of Liège, Belgium.
He is a member of the American College of Rheumatology, the Osteoarthritis Research Society International (OARSI), the French Society of Rheumatology and the International Cartilage Repair Society (ICRS). Between 2006 and 2013 he was a member of the board of directors of OARSI, the premier organization focused on the prevention, diagnosis and treatment of OA. Prof. Henrotin was involved in the development of the OARSI recommendations for non-surgical treatment of OA, guidelines for physical function assessment in OA patients and recommendations on biomarker application in the development of OA drugs. He was chairman of the World Bone, Muscle & Joint Disease (BMJD) debate and consensus congress in 2010 and 2012 and chairman of the 2010 OARSI world congress.
Prof. Henrotin is also vice president of the spine section and the OA section of the French Society of Rheumatology since 2008, board member of the French Society of Rheumatology since 2011 and former president of the Belgium Back Society. He was the Belgian delegate and board member of the COST B13 action “Low back pain: guidelines for its management” organized by European Commission Research Directorate General. He is co-president of the board of the National Council of Physical Therapy and Rehabilitation for the Belgian Health Ministry and deputy chair of the communication and publicity committee of the International Cartilage Regeneration & Joint Preservation Society (ICRS). Prof. Henrotin is the founder and president of the Osteoarthritis Foundation, a nonprofit organization mainly devoted to fighting OA by increasing patient education and awareness as well as supporting OA research to improve understanding of OA pathology and to augment therapeutic modalities to prevent OA and reduce OA-related disabilities.
Prof. Henrotin has published over 250 scientific, peer-reviewed papers and 10 book chapters. He serves on the editorial boards of several scientific journals including “Osteoarthritis and Cartilage”, “Osteoarthritis and Cartilage Open”, “Journal of Experimental Orthopaedics” and “Annals of Physical and Rehabilitation Medicine”. In 2005, he received the “De Cooman” award for his work on the pathogenesis and treatment of OA and an award from the International Cartilage repair Society (ICRS) for his work on Syndecan-4 in 2019.
Prof. Henrotin was also the founder of two spin-off companies of the University of Liège: Artialis SA, a company specialized in pre-clinical and clinical research and development in the field of OA and other musculoskeletal disorders, with special expertise in the development and use of biological markers of musculoskeletal disorders, and KiOmed Pharma (former Synolyne Pharma), a company developing medical devices for joint viscosupplementation and tissue repair.
Prof. Henrotin advises GeneQuine on the clinical development strategy of the company’s lead product GQ-303 for the treatment of osteoarthritis as well as GeneQuine’s gene therapy program for intervertebral disc degeneration.